[go: up one dir, main page]

BR0211265A - Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor - Google Patents

Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor

Info

Publication number
BR0211265A
BR0211265A BR0211265-5A BR0211265A BR0211265A BR 0211265 A BR0211265 A BR 0211265A BR 0211265 A BR0211265 A BR 0211265A BR 0211265 A BR0211265 A BR 0211265A
Authority
BR
Brazil
Prior art keywords
preparation
antitumor agents
phenylacetamido
thiazole derivatives
compounds
Prior art date
Application number
BR0211265-5A
Other languages
English (en)
Inventor
Paolo Pevarello
Raffaella Amici
Manuela Villa
Anna Vulpetti
Barbara Salom
Mario Varasi
Maria Gabriella Brasca
Gabriella Traquandi
Marcella Nesi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0211265A publication Critical patent/BR0211265A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"DERIVADOS DE FENILACETAMIDO-TIAZOL, PROCESSO PARA SUA PREPARAçãO E O SEU USO COMO AGENTES ANTITUMOR". A presente invenção se refere aos compostos representados pela fórmula (I), conforme definidos na descrição, em que R é um átomo de hidrogênio ou um grupo metil e R1 é um grupo como definido na especificação, ou um sal farmaceuticamente aceitável do mesmo, são revelados, os ditos compostos são úteis no tratamento de desordens proliferativas das células, como por exemplo, câncer associado a uma atividade de cinase alterada dependente do ciclo da célula.
BR0211265-5A 2001-07-19 2002-07-02 Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor BR0211265A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90794701A 2001-07-19 2001-07-19
US35764202P 2002-02-20 2002-02-20
PCT/EP2002/007289 WO2003008365A2 (en) 2001-07-19 2002-07-02 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents

Publications (1)

Publication Number Publication Date
BR0211265A true BR0211265A (pt) 2004-07-20

Family

ID=26999733

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211265-5A BR0211265A (pt) 2001-07-19 2002-07-02 Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor

Country Status (25)

Country Link
US (1) US20040235919A1 (pt)
EP (1) EP1406899B1 (pt)
JP (1) JP2004534857A (pt)
KR (1) KR100908794B1 (pt)
CN (1) CN1286835C (pt)
AR (1) AR036176A1 (pt)
AT (1) ATE345341T1 (pt)
AU (1) AU2002325860B2 (pt)
BR (1) BR0211265A (pt)
CA (1) CA2453294A1 (pt)
CY (1) CY1105948T1 (pt)
CZ (1) CZ2004107A3 (pt)
DE (1) DE60216097T2 (pt)
DK (1) DK1406899T3 (pt)
EA (1) EA007392B1 (pt)
ES (1) ES2274076T3 (pt)
GE (1) GEP20105095B (pt)
HK (1) HK1068336A1 (pt)
IL (2) IL159570A0 (pt)
MX (1) MXPA04000407A (pt)
NO (1) NO20040210L (pt)
NZ (1) NZ530524A (pt)
PL (1) PL367938A1 (pt)
PT (1) PT1406899E (pt)
WO (1) WO2003008365A2 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
CA2576599A1 (en) * 2004-08-17 2006-02-23 F. Hoffmann-La Roche Ag Substituted hydantoins
US7550598B2 (en) 2004-08-18 2009-06-23 Takeda Pharmaceutical Company Limited Kinase inhibitors
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
MX2014014253A (es) 2012-05-21 2015-02-17 Novartis Ag Novedosas n-piridinil-amidas sustituidas en el anillo como inhibidoras de cinasa.
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
UA120592C2 (uk) 2013-07-03 2020-01-10 Каріофарм Терапеутікс Інк. Заміщені бензофуранільні та бензоксазолільні сполуки та їхнє застосування
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
EA201890524A1 (ru) 2015-08-18 2018-07-31 Кариофарм Терапевтикс Инк. (s,e)-3-(6-аминопиридин-3-ил)-n-((5-(4-(3-фтор-3-метилпирролидин-1-карбонил)фенил)-7-(4-фторфенил)бензофуран-2-ил)метил)акриламид для лечения рака
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
KR102130253B1 (ko) 2018-09-17 2020-07-03 영진약품 주식회사 신규한 티아졸 유도체 및 이의 약학적으로 허용가능한 염
WO2021182914A1 (ko) * 2020-03-13 2021-09-16 영진약품 주식회사 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염
CN112979636A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含苯硫醚结构的噻唑类化合物及其制备方法和应用
CN112979634A (zh) * 2021-02-06 2021-06-18 绍兴文理学院 一种含酰胺结构的噻唑类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6214852B1 (en) * 1998-10-21 2001-04-10 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents

Also Published As

Publication number Publication date
EP1406899A2 (en) 2004-04-14
DE60216097T2 (de) 2007-06-28
NO20040210L (no) 2004-03-03
PL367938A1 (en) 2005-03-07
GEP20105095B (en) 2010-10-25
CN1286835C (zh) 2006-11-29
WO2003008365A3 (en) 2004-02-12
MXPA04000407A (es) 2004-03-18
EP1406899B1 (en) 2006-11-15
DK1406899T3 (da) 2007-04-02
CN1531535A (zh) 2004-09-22
KR20040030821A (ko) 2004-04-09
PT1406899E (pt) 2007-01-31
IL204947A0 (en) 2010-11-30
CZ2004107A3 (cs) 2004-04-14
NZ530524A (en) 2006-12-22
JP2004534857A (ja) 2004-11-18
EA007392B1 (ru) 2006-10-27
IL159570A0 (en) 2004-06-01
HK1068336A1 (en) 2005-04-29
AR036176A1 (es) 2004-08-18
CA2453294A1 (en) 2003-01-30
WO2003008365A2 (en) 2003-01-30
CY1105948T1 (el) 2011-04-06
ATE345341T1 (de) 2006-12-15
DE60216097D1 (de) 2006-12-28
US20040235919A1 (en) 2004-11-25
KR100908794B1 (ko) 2009-07-22
EA200400208A1 (ru) 2004-06-24
ES2274076T3 (es) 2007-05-16
AU2002325860B2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
BR0211265A (pt) Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor
BR0317455A (pt) Derivados de pirrol-pirazol substituìdos como inibidores de quinase
BRPI0416605A (pt) composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0112224A (pt) Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BRPI0410760A (pt) compostos, processo para fabricação dos mesmos, composições farmacêuticas e uso deste compostos
BRPI0416004A (pt) composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
PE20020104A1 (es) Derivados de benzotiazol
BR0109703A (pt) Derivados de piperazina
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
BR0009864A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
BRPI0410238A (pt) compostos orgánicos
BR0212484A (pt) Composto, processo para a preparação e uso do mesmo, método de tratamento de distúrbios alimentares em um animal de sangue quente, e, composição farmacêutica
BR0309012A (pt) Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso
BR0014808A (pt) Processos de preparação de um composto, e, compostos nitroaromáticos
BRPI0410050A (pt) método de tratamento ou de profilaxia de distúrbios psicóticos, distúrbios de prejuìzo intelectual ou doenças ou condições nos quais a modulação do receptor alfa7-nicotìnico é benéfica, composição farmacêutica, método de tratamento ou de profilaxia de doenças, uso de um composto, composto, e, método de preparação de um composto
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI C07C 49/00, A61P 35/00

Ipc: C07C 49/00 (2011.01), A61P 35/00 (2011.01)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.